- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.10. | OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain | 353 | GlobeNewswire (Europe) | NEPTUNE is evaluating urcosimod as a potential first-in-class treatment for neuropathic corneal painFirst patients enrolled by Dr. Melissa Toyos at Toyos Clinic in Nashville, TN
LONDON and NEW YORK... ► Artikel lesen | |
| 06.10. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 29.09. | OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences | 357 | GlobeNewswire (Europe) | OKYO demonstrates continued commitment to optometry and ophthalmology
LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| 29.09. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 09.09. | OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026 | 405 | GlobeNewswire (Europe) | Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal painLONDON and NEW YORK, Sept. 09,... ► Artikel lesen | |
| 08.09. | OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference | 415 | GlobeNewswire (Europe) | LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 08.09. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 28.07. | OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer | 303 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| 27.07. | OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 | 392 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 27.07. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.07. | OKYO Pharma Announces Purchase of Shares by Director | 372 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 23.07. | OKYO Pharma CEO purchases 15,000 shares at $1.54 each | 2 | Investing.com | ||
| 23.07. | OKYO Pharma Announces Purchase of Shares by Chief Executive Officer | 358 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 22.07. | OKYO Pharma Announces Purchase of Shares by Chairman | 353 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 22.07. | OKYO Pharma executive purchases 3,500 shares at $1.40 each | 2 | Investing.com | ||
| 22.07. | OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director | 362 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 22.07. | OKYO Pharma Announces Purchase of Shares by Chief Medical Officer | 354 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 21.07. | OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference | 428 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 21.07. | OKYO Pharma chairman increases stake with share purchase | 2 | Seeking Alpha | ||
| 21.07. | OKYO Pharma Announces Purchase of Shares by Chairman | 412 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,540 | +0,32 % | Valneva bekommt eine 3-: Warum unsere Experten so vorsichtig urteilen - Mein Rat: sofort handeln! | ||
| PALATIN TECHNOLOGIES | 5,110 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| OCUGEN | 0,684 | -3,53 % | Ocugen mit BRANDMELDUNG: Folgt jetzt der nächste Kursrutsch? - Handeln Sie, bevor es zu spät ist! | ||
| VIVORYON THERAPEUTICS | 0,826 | 0,00 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,280 | -0,23 % | H.C. Wainwright bekräftigt Verkaufsempfehlung für Sarepta Therapeutics - Kursziel 5 US-Dollar | ||
| IDEXX LABORATORIES | 519,00 | +1,37 % | Here's How IDEXX Laboratories Is Placed Ahead of Q3 Earnings | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,517 | +0,08 % | Here's Why You Should Hold PacBio Stock in Your Portfolio for Now | ||
| REDHILL BIOPHARMA | 0,404 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,600 | +1,54 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights | Ocular's AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence... ► Artikel lesen | |
| VERASTEM | 8,676 | -1,57 % | Novocure and Verastem to Test Combined Therapies for Locally Advanced Pancreatic Cancer | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,830 | -1,53 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,360 | +0,85 % | Rocket Pharma upgraded at Goldman Sachs on Danon disease therapy | ||
| BIOXCEL THERAPEUTICS | 0,065 | 0,00 % | Teva Completes Acquisition of BioXcel Assets, Expands Neuroscience Pipeline | ||
| VOYAGER THERAPEUTICS | 1,633 | -0,73 % | Voyager Therapeutics, Inc.: Voyager's Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer's Disease to Be Featured in Poster Presentations at CTAD 2026 | ||
| PALISADE BIO | 1,180 | -1,26 % | Palisade Bio doses first patient in ulcerative colitis trial |
Das Unternehmen OKYO PHARMA LIMITED kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,500 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.